Combined prophylactic and therapeutic cancer vaccine: Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice

Jiahua Qian, Yujun Dong, Yuk Ying S. Pang, Ramy Ibrahim, Jay A. Berzofsky, John T. Schiller, Samir N. Khleif

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

We identified the strategies to induce a CTL response to human papillomavirus (HPV) 16 E2 in HLA-A2 transgenic mice (AAD). A chimeric HPV16 virus-like particle (VLP) that includes full length HPV16 E7 and E2 (VLP-E7E2) was generated. The combination of E2 and E7 has the advantage that E2 is expressed in early dysplasia and neoplasia lesions, where E7 is expressed in more advance lesions. Since T cell response to E2 is less defined, we first evaluated the strategies to enhancing CD8+ T cell responses to HPV E7, using different combinations of immune-modulators with VLP-E7E2. Data showed that the CTL response to E7 could be significantly enhanced by coinjection of GM-CSF and antiCD40 antibodies with chimeric VLP-E7E2 without adjuvant. However, using the same combination, a low level of CD8+ T cell response to E2 was detected. To enhance the CD8+ T cell response to E2, we analyzed T cell epitopes from E2 sequence. A heterogonous prime-boost with chimeric VLP-E7E2 and E2 peptides was performed. The data showed that the priming with chimeric VLP-E7E2, followed by boosting with E2 peptides, gave a better CTL response than 2 immunizations with E2 peptides. The enhanced immunity is due to the increase of CD11c+ and CD11c+ CD40 + double positive dendritic cells in mice that received immune-modulators, GM-CSF and antiCD40. Furthermore, the level of anti-L1 antibodies remains similar in mice immunized with chimeric VLP with/without immune-modulators. Thus, the data suggested that the chimeric VLP-E7E2 has a therapeutic potential for the treatment of HPV-associated CINs and cancer without diminishing VLPs potential as a prophylactic vaccine by inducing anti-L1 antibodies against free virus.

Original languageEnglish (US)
Pages (from-to)3022-3029
Number of pages8
JournalInternational Journal of Cancer
Volume118
Issue number12
DOIs
StatePublished - Jun 15 2006

Fingerprint

HLA-A2 Antigen
Cancer Vaccines
Virion
T-Lymphocytes
Therapeutics
Granulocyte-Macrophage Colony-Stimulating Factor
Peptides
Anti-Idiotypic Antibodies
T-Lymphocyte Epitopes
Human papillomavirus 16
Dendritic Cells
Transgenic Mice
Immunity
Immunization
Neoplasms
Vaccines
Viruses
Antibodies

Keywords

  • CTL
  • Chimeric VLP
  • Dendritic cells
  • HPV 16
  • HPV 16 E2
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Qian, J., Dong, Y., Pang, Y. Y. S., Ibrahim, R., Berzofsky, J. A., Schiller, J. T., & Khleif, S. N. (2006). Combined prophylactic and therapeutic cancer vaccine: Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. International Journal of Cancer, 118(12), 3022-3029. https://doi.org/10.1002/ijc.21781

Combined prophylactic and therapeutic cancer vaccine : Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. / Qian, Jiahua; Dong, Yujun; Pang, Yuk Ying S.; Ibrahim, Ramy; Berzofsky, Jay A.; Schiller, John T.; Khleif, Samir N.

In: International Journal of Cancer, Vol. 118, No. 12, 15.06.2006, p. 3022-3029.

Research output: Contribution to journalArticle

Qian, J, Dong, Y, Pang, YYS, Ibrahim, R, Berzofsky, JA, Schiller, JT & Khleif, SN 2006, 'Combined prophylactic and therapeutic cancer vaccine: Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice', International Journal of Cancer, vol. 118, no. 12, pp. 3022-3029. https://doi.org/10.1002/ijc.21781
Qian, Jiahua ; Dong, Yujun ; Pang, Yuk Ying S. ; Ibrahim, Ramy ; Berzofsky, Jay A. ; Schiller, John T. ; Khleif, Samir N. / Combined prophylactic and therapeutic cancer vaccine : Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. In: International Journal of Cancer. 2006 ; Vol. 118, No. 12. pp. 3022-3029.
@article{d0bf6678576e46059c49c37bc0258a44,
title = "Combined prophylactic and therapeutic cancer vaccine: Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice",
abstract = "We identified the strategies to induce a CTL response to human papillomavirus (HPV) 16 E2 in HLA-A2 transgenic mice (AAD). A chimeric HPV16 virus-like particle (VLP) that includes full length HPV16 E7 and E2 (VLP-E7E2) was generated. The combination of E2 and E7 has the advantage that E2 is expressed in early dysplasia and neoplasia lesions, where E7 is expressed in more advance lesions. Since T cell response to E2 is less defined, we first evaluated the strategies to enhancing CD8+ T cell responses to HPV E7, using different combinations of immune-modulators with VLP-E7E2. Data showed that the CTL response to E7 could be significantly enhanced by coinjection of GM-CSF and antiCD40 antibodies with chimeric VLP-E7E2 without adjuvant. However, using the same combination, a low level of CD8+ T cell response to E2 was detected. To enhance the CD8+ T cell response to E2, we analyzed T cell epitopes from E2 sequence. A heterogonous prime-boost with chimeric VLP-E7E2 and E2 peptides was performed. The data showed that the priming with chimeric VLP-E7E2, followed by boosting with E2 peptides, gave a better CTL response than 2 immunizations with E2 peptides. The enhanced immunity is due to the increase of CD11c+ and CD11c+ CD40 + double positive dendritic cells in mice that received immune-modulators, GM-CSF and antiCD40. Furthermore, the level of anti-L1 antibodies remains similar in mice immunized with chimeric VLP with/without immune-modulators. Thus, the data suggested that the chimeric VLP-E7E2 has a therapeutic potential for the treatment of HPV-associated CINs and cancer without diminishing VLPs potential as a prophylactic vaccine by inducing anti-L1 antibodies against free virus.",
keywords = "CTL, Chimeric VLP, Dendritic cells, HPV 16, HPV 16 E2, Vaccine",
author = "Jiahua Qian and Yujun Dong and Pang, {Yuk Ying S.} and Ramy Ibrahim and Berzofsky, {Jay A.} and Schiller, {John T.} and Khleif, {Samir N.}",
year = "2006",
month = "6",
day = "15",
doi = "10.1002/ijc.21781",
language = "English (US)",
volume = "118",
pages = "3022--3029",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Combined prophylactic and therapeutic cancer vaccine

T2 - Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice

AU - Qian, Jiahua

AU - Dong, Yujun

AU - Pang, Yuk Ying S.

AU - Ibrahim, Ramy

AU - Berzofsky, Jay A.

AU - Schiller, John T.

AU - Khleif, Samir N.

PY - 2006/6/15

Y1 - 2006/6/15

N2 - We identified the strategies to induce a CTL response to human papillomavirus (HPV) 16 E2 in HLA-A2 transgenic mice (AAD). A chimeric HPV16 virus-like particle (VLP) that includes full length HPV16 E7 and E2 (VLP-E7E2) was generated. The combination of E2 and E7 has the advantage that E2 is expressed in early dysplasia and neoplasia lesions, where E7 is expressed in more advance lesions. Since T cell response to E2 is less defined, we first evaluated the strategies to enhancing CD8+ T cell responses to HPV E7, using different combinations of immune-modulators with VLP-E7E2. Data showed that the CTL response to E7 could be significantly enhanced by coinjection of GM-CSF and antiCD40 antibodies with chimeric VLP-E7E2 without adjuvant. However, using the same combination, a low level of CD8+ T cell response to E2 was detected. To enhance the CD8+ T cell response to E2, we analyzed T cell epitopes from E2 sequence. A heterogonous prime-boost with chimeric VLP-E7E2 and E2 peptides was performed. The data showed that the priming with chimeric VLP-E7E2, followed by boosting with E2 peptides, gave a better CTL response than 2 immunizations with E2 peptides. The enhanced immunity is due to the increase of CD11c+ and CD11c+ CD40 + double positive dendritic cells in mice that received immune-modulators, GM-CSF and antiCD40. Furthermore, the level of anti-L1 antibodies remains similar in mice immunized with chimeric VLP with/without immune-modulators. Thus, the data suggested that the chimeric VLP-E7E2 has a therapeutic potential for the treatment of HPV-associated CINs and cancer without diminishing VLPs potential as a prophylactic vaccine by inducing anti-L1 antibodies against free virus.

AB - We identified the strategies to induce a CTL response to human papillomavirus (HPV) 16 E2 in HLA-A2 transgenic mice (AAD). A chimeric HPV16 virus-like particle (VLP) that includes full length HPV16 E7 and E2 (VLP-E7E2) was generated. The combination of E2 and E7 has the advantage that E2 is expressed in early dysplasia and neoplasia lesions, where E7 is expressed in more advance lesions. Since T cell response to E2 is less defined, we first evaluated the strategies to enhancing CD8+ T cell responses to HPV E7, using different combinations of immune-modulators with VLP-E7E2. Data showed that the CTL response to E7 could be significantly enhanced by coinjection of GM-CSF and antiCD40 antibodies with chimeric VLP-E7E2 without adjuvant. However, using the same combination, a low level of CD8+ T cell response to E2 was detected. To enhance the CD8+ T cell response to E2, we analyzed T cell epitopes from E2 sequence. A heterogonous prime-boost with chimeric VLP-E7E2 and E2 peptides was performed. The data showed that the priming with chimeric VLP-E7E2, followed by boosting with E2 peptides, gave a better CTL response than 2 immunizations with E2 peptides. The enhanced immunity is due to the increase of CD11c+ and CD11c+ CD40 + double positive dendritic cells in mice that received immune-modulators, GM-CSF and antiCD40. Furthermore, the level of anti-L1 antibodies remains similar in mice immunized with chimeric VLP with/without immune-modulators. Thus, the data suggested that the chimeric VLP-E7E2 has a therapeutic potential for the treatment of HPV-associated CINs and cancer without diminishing VLPs potential as a prophylactic vaccine by inducing anti-L1 antibodies against free virus.

KW - CTL

KW - Chimeric VLP

KW - Dendritic cells

KW - HPV 16

KW - HPV 16 E2

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=33646413939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646413939&partnerID=8YFLogxK

U2 - 10.1002/ijc.21781

DO - 10.1002/ijc.21781

M3 - Article

C2 - 16425257

AN - SCOPUS:33646413939

VL - 118

SP - 3022

EP - 3029

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 12

ER -